AOD-9604 in Sully — Fat Loss Peptide Research Guide
AOD-9604 research guide for Sully. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't found on pharmacy shelves in Sully or virtually any local market — this is a specialist compound available through a dedicated online market. The practical takeaway for Sully researchers: sourcing AOD-9604 comes down completely to vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. Separating properly characterised AOD-9604 from the rest of the market comes down to three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Sully researchers need to know about purchasing, testing, and working with AOD-9604 for legitimate research applications.
How AOD-9604 Works — Mechanisms & Research
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Sully studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
AOD-9604 Purchasing Guide
Before looking at individual vendors, understand what genuine quality documentation contains — so you can identify whether a supplier meets the standard. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. The combination of community consensus and independent COA review is the gold standard for AOD-9604 sourcing — community feedback surfaces patterns individual COA review misses, and vice versa. The dry lyophilised powder of AOD-9604 is always preferable to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations degrade within weeks even when refrigerated.
Order AOD-9604 — ships to Sully
COA-verified · International tracking · Research grade
All use of AOD-9604 in Sully or anywhere is research use only — this compound is not approved for human therapeutic use, and all handling should adhere to research compound handling standards. Temperature excursions — even temporary temperature deviation — can cause partial degradation without any obvious sign; always use only material shipped with appropriate cold protection. Bacterial endotoxin contamination is the most serious safety risk associated with research-grade peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. PubMed represent the most comprehensive research databases for AOD-9604 research; focus on peer-reviewed publications with documented compound quality over case reports or anecdotal evidence.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
